Galapagos NV Launching Phase 1 Trial for Dual Action Anti-inflammatory Molecule
Galapagos NV's potential new therapy for inflammatory bowel disease (IBD) — which stimulates anti-inflammatory signals while inhibiting pro-inflammatory ones — will move into Phase 1 clinical testing, the company announced.
The trial (NCT04106297), now recruiting participants in Belgium, will test the safety and tolerability of a second-generation molecule called GLPG3970. The molecule has successfully shown preclinical activity against a variety of inflammatory-based conditions, including psoriasis, rheumatoid arthritis, and IBD.
IBD is a general term used to describe several chronic inflammatory disorders of the digestive tract. There are two main types of IBD: Crohn’s disease, characterized by inflammation of the digestive tract lining, and